Literature DB >> 9806429

Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice.

X M Li1, G Metzger, E Filipski, G Lemaigre, F Lévi.   

Abstract

The relationship between the rhythm in tissue nonprotein sulphydryl groups (NPSH) and that in 1,2-diamine (trans-I)-cyclohexane oxalatoplatinum (1-OHP) toxicity was investigated in a total of 266 male B6D2F1 mice, using buthionine sulphoximine (BSO), an inhibitor of gamma-glutamylcysteine synthetase. Mice were synchronized with an alternation of 12 h light (L) and 12 h darkness (D; LD 12:12), and circadian time was expressed in hours after light onset (HALO). NPSH was measured in liver, jejunum and bone marrow at 0, 8 and 16 HALO. Dosing 1-OHP at these times achieved intermediate. high or low toxicity respectively. The physiological circadian rhythm in NPSH content was statistically significant in all tissues studied, with a maximum at the transition from D to L (0 HALO). BSO administration (450 mg/kg i.p., 4 h before sampling) induced a large depletion in liver and jejunum NPSH at their physiological peak (0 HALO), but exerted no significant effect at their trough (8 HALO). As a result, 24 h rhythm was suppressed in liver and jejunum, but remained similar to the physiological one in bone marrow. BSO enhanced 1-OHP-induced mortality and jejunal toxicity, but exerted no significant effect upon bone marrow toxicity. Despite these differences, 1-OHP remained least toxic at 16 HALO, near the middle of the dark span, which corresponds to maximum activity in the circadian rest/activity cycle. Our results show that mean NPSH levels in liver seem to account for the mean level of 1-OHP toxicity, while jejunal NPSH rhythm plays an important role in the intestinal toxicity rhythm of this drug.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806429     DOI: 10.1007/s002040050545

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  3 in total

Review 1.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

Authors:  F Lévi; G Metzger; C Massari; G Milano
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

2.  Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.

Authors:  T G Granda; R-M D'Attino; E Filipski; P Vrignaud; C Garufi; E Terzoli; M-C Bissery; F Lévi
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

Review 3.  Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy.

Authors:  Narin Ozturk; Dilek Ozturk; Ibrahim Halil Kavakli; Alper Okyar
Journal:  Int J Mol Sci       Date:  2017-10-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.